LoadingLoadingLoading40 funds hold it.Insiders net selling.
Net selling: insiders sold $45.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $8K to $120K in total in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 13, 2026
Financial period
Q3 2026
Earnings per share
$2.52 expected
Revenue
$25.38B expected
FY2026 guidance
$101.00B to $101.40B
No comparable estimate
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 27, 2026Reported Oct 13, 2026 | $2.59est. $2.52 | +2.69%beat | $25.40Best. $25.38B+0.07% | +5.9%from $23.99B |
| Jun 28, 2026Reported Jul 15, 2026 | $2.90est. $2.85 | +1.58%beat | $25.31BCompany release | +6.6%from $23.74B |
| Mar 29, 2026Reported Apr 14, 2026 | $2.70est. $2.68 | +0.85%in line | $24.06BSEC filing | +9.9%from $21.89B |
| Dec 31, 2025Reported Jan 21, 2026 | $2.46est. $2.46 | -0.11%in line | $24.56BAlpha Vantage | +9.1%from $22.52B |
| Sep 28, 2025Reported Oct 14, 2025 | $2.80est. $2.76 | +1.45%beat | $23.99BSEC filing | +6.8%from $22.47B |
| Jun 29, 2025Reported Jul 16, 2025 | $2.77est. $2.68 | +3.36%beat | $23.74BSEC filing | +5.8%from $22.45B |
| Mar 30, 2025Reported Apr 15, 2025 | $2.77est. $2.58 | +7.36%beat | $21.89BSEC filing | +2.4%from $21.38B |
| Dec 31, 2024Reported Jan 22, 2025 | $2.04est. $2.01 | +1.49%beat | $22.52BAlpha Vantage | +5.3%from $21.39B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $24.56B | $24.06B | $25.31B | $25.40B |
| Cost of what it sold | $7.97B | $8.11B | $8.05B | $6.86B |
| Gross profit | $16.60B | $15.96B | $17.26B | $18.54B |
| What it spent | ||||
| Research and development | $4.25B | $3.53B | $3.65B | $4.65B |
| Sales and admin | $6.95B | $6.03B | $6.43B | $6.29B |
| Other operating costs | -$200.0M | — | — | $1.24B |
| Total operating expenses | $11.01B | $9.56B | $10.09B | $12.18B |
| What was left | ||||
| Operating profit | $5.59B | $6.39B | $7.17B | $6.37B |
| Interest on debt | $214.0M | $272.0M | $281.0M | $31.0M |
| Profit before tax | $4.97B | $5.99B | $6.75B | $34.0M |
| Tax | -$150.0M | $755.0M | $1.21B | -$176.0M |
| Net profit | $5.12B | $5.24B | $5.53B | $210.0M |
| EBITDA | $7.19B | $8.27B | $8.99B | $6.37B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
RevMed’s Rasonque shatters analyst estimates with $198M quarter
NeutralNov 5Bristol Myers Squibb (BMY) Brings First FDA Approved CELMoD to Multiple Myeloma Patients
NeutralNov 5Zimmer Biomet Q3: Hips And Robotics Lift Guidance As Knees Lag; Monogram Launch Moves Up
NeutralNov 5Are You Overpaying For Abbott Stock Versus Its Rivals?
NeutralNov 5What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Nov. 3
Leans bullishNov 5Nanobiotix shares rise 3% and rank among the top performers of the SBF 120
Leans bullishNov 5Bristol Myers Squibb Company $BMY Shares Sold by AIA Group Ltd
NeutralNov 5Legend Biotech Announces Seven Presentations on CARVYKTI and Pipeline at ASH 2026
Leans bullishNov 430 macro signals shaping JNJ right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
